Immuno-PET Imaging and Pharmacokinetics of an Anti-CEA scFv-based Trimerbody and Its Monomeric Counterpart in Human Gastric Carcinoma-Bearing Mice
Open Access
- 6 February 2019
- journal article
- research article
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 16 (3) , 1025-1035
Abstract
Monoclonal antibodies (mAbs) are currently used as therapeutic agents in different types of cancer. However, mAbs and antibody fragments developed so far show suboptimal properties in terms of circulation time and tumor penetration/retention. Here, we report the radiolabeling, pharmacokinetic evaluation, and determination of tumor targeting capacity of the previously validated anti-CEA MFE23-scFv-based N-terminal trimerbody (MFE23N-trimerbody), and the results are compared to those obtained for the monomeric MFE23-scFv. Dissection and gamma-counting studies performed with the 131I-labeled protein scaffolds in normal mice showed slower blood clearance for the trimerbody, and accumulation in the kidneys, the spleen and the liver for both species. These, together with a progressive uptake in the small intestine, confirm a combined elimination scheme with hepatobiliary and urinary excretion. Positron emission tomography studies performed in a xenograft mouse model of human gastric adenocarcinoma, generated by subcutaneous administration of CEA-positive human MKN45 cells, showed higher tumor accumulation and tumor-to-muscle (T/M) ratios for 124I-labeled MFE23N-trimerbody than for MFE23-scFv. Specific uptake was not detected with PET imaging in CEA negative xenografts as indicated by low T/M ratios. Our data suggest that engineered intermediate-sized trivalent antibody fragments could be promising candidates for targeted therapy and imaging of CEA-positive tumors.Keywords
Funding Information
- Sundhed og Sygdom, Det Frie Forskningsr?d (DFF-6110-00533)
- Ministerio de Ciencia e Innovaci?n (MDM-2017-0720)
- Secretar?a de Estado de Investigaci?n, Desarrollo e Innovaci?n (CTQ2017-87637-R, PCIN-2015-116)
This publication has 44 references indexed in Scilit:
- Generation and characterization of monospecific and bispecific hexavalent trimerbodiesmAbs, 2013
- Pharmacokinetics and Biodistribution Study of 7A7 Anti-Mouse Epidermal Growth Factor Receptor Monoclonal Antibody and Its Fragment in an Immunocompetent Mouse ModelISRN Pharmacology, 2012
- The production, characterisation and enhanced pharmacokinetics of scFv–albumin fusions expressed in Saccharomyces cerevisiaeProtein Expression and Purification, 2010
- Antibody Vectors for ImagingSeminars in Nuclear Medicine, 2010
- Crystal Structure of Human Collagen XVIII Trimerization Domain: A Novel Collagen Trimerization FoldJournal of Molecular Biology, 2009
- In Vivo Tumor Targeting and Imaging with Engineered Trivalent Antibody Fragments Containing Collagen-Derived SequencesPLOS ONE, 2009
- Targeted killing of colorectal cancer cell lines by a humanised IgG1 monoclonal antibody that binds to membrane-bound carcinoembryonic antigenBritish Journal of Cancer, 2008
- A Versatile Bifunctional Chelate for Radiolabeling Humanized Anti-CEA Antibody with In-111 and Cu-64 at Either Thiol or Amino Groups: PET Imaging Of CEA-Positive Tumors with Whole AntibodiesBioconjugate Chemistry, 2007
- Antiepidermal growth factor variant III scFv fragment: effect of radioiodination method on tumor targeting and normal tissue clearanceNuclear Medicine and Biology, 2006
- Engineered antibody fragments and the rise of single domainsNature Biotechnology, 2005